Egyptian International Pharmaceutical Industries Company (EGX:PHAR)
Egypt
· Delayed Price · Currency is EGP 84.50
+1.51 (1.82%)
At close: Apr 28, 2026
EGX:PHAR Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 9,441 | 7,591 | 5,232 | 3,955 | 3,409 | Upgrade
|
| Revenue Growth (YoY) | 24.38% | 45.09% | 32.27% | 16.03% | 18.13% | Upgrade
|
| Cost of Revenue | 5,300 | 4,244 | 2,983 | 2,397 | 1,957 | Upgrade
|
| Gross Profit | 4,141 | 3,346 | 2,248 | 1,558 | 1,452 | Upgrade
|
| Selling, General & Admin | 1,248 | 1,065 | 788.09 | 683.2 | 566.08 | Upgrade
|
| Research & Development | 70.94 | 70.45 | 43.23 | 43.68 | 34.96 | Upgrade
|
| Other Operating Expenses | 105 | 378.57 | 167.2 | 134.35 | 60.79 | Upgrade
|
| Operating Expenses | 1,800 | 1,844 | 1,038 | 896.23 | 674.83 | Upgrade
|
| Operating Income | 2,341 | 1,503 | 1,211 | 662 | 776.85 | Upgrade
|
| Interest Expense | -1,333 | -928.54 | -388.52 | -195.42 | -136.25 | Upgrade
|
| Interest & Investment Income | 139.67 | 72.05 | 26.24 | 57.77 | 32.11 | Upgrade
|
| Earnings From Equity Investments | 495.5 | 151.58 | 74.51 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -16.17 | 699.88 | 139.63 | 286.4 | -6.25 | Upgrade
|
| Other Non Operating Income (Expenses) | 142.09 | 11.04 | 1.51 | -20.62 | -24.04 | Upgrade
|
| EBT Excluding Unusual Items | 1,769 | 1,509 | 1,064 | 790.13 | 642.41 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.76 | 0.22 | 4.69 | 3.7 | 2.78 | Upgrade
|
| Pretax Income | 1,771 | 1,509 | 1,069 | 793.83 | 645.19 | Upgrade
|
| Income Tax Expense | 313.04 | 411.83 | 245.62 | 150.07 | 156.9 | Upgrade
|
| Earnings From Continuing Operations | 1,458 | 1,097 | 823.31 | 643.76 | 488.29 | Upgrade
|
| Minority Interest in Earnings | -16.24 | -1.21 | -0.99 | -0.78 | -0.53 | Upgrade
|
| Net Income | 1,442 | 1,096 | 822.32 | 642.98 | 487.75 | Upgrade
|
| Net Income to Common | 1,442 | 1,096 | 822.32 | 642.98 | 487.75 | Upgrade
|
| Net Income Growth | 31.57% | 33.25% | 27.89% | 31.83% | 0.25% | Upgrade
|
| Shares Outstanding (Basic) | 162 | 149 | 149 | 99 | 99 | Upgrade
|
| Shares Outstanding (Diluted) | 162 | 149 | 149 | 99 | 99 | Upgrade
|
| Shares Change (YoY) | 9.01% | - | 50.00% | - | 1.64% | Upgrade
|
| EPS (Basic) | 8.89 | 7.37 | 5.53 | 6.48 | 4.92 | Upgrade
|
| EPS (Diluted) | 8.89 | 7.37 | 5.53 | 6.48 | 4.92 | Upgrade
|
| EPS Growth | 20.69% | 33.25% | -14.74% | 31.83% | -1.36% | Upgrade
|
| Free Cash Flow | -261.15 | -4,121 | -2,198 | -859.77 | -53.27 | Upgrade
|
| Free Cash Flow Per Share | -1.61 | -27.70 | -14.77 | -8.67 | -0.54 | Upgrade
|
| Dividend Per Share | - | 1.500 | 1.000 | 1.000 | 1.500 | Upgrade
|
| Dividend Growth | - | 50.00% | - | -33.33% | - | Upgrade
|
| Gross Margin | 43.86% | 44.09% | 42.98% | 39.40% | 42.59% | Upgrade
|
| Operating Margin | 24.80% | 19.79% | 23.14% | 16.74% | 22.79% | Upgrade
|
| Profit Margin | 15.27% | 14.44% | 15.72% | 16.26% | 14.31% | Upgrade
|
| Free Cash Flow Margin | -2.77% | -54.29% | -42.01% | -21.74% | -1.56% | Upgrade
|
| EBITDA | 2,455 | 1,599 | 1,314 | 759.39 | 867.73 | Upgrade
|
| EBITDA Margin | 26.01% | 21.07% | 25.12% | 19.20% | 25.46% | Upgrade
|
| D&A For EBITDA | 114.4 | 96.53 | 103.17 | 97.39 | 90.88 | Upgrade
|
| EBIT | 2,341 | 1,503 | 1,211 | 662 | 776.85 | Upgrade
|
| EBIT Margin | 24.80% | 19.79% | 23.14% | 16.74% | 22.79% | Upgrade
|
| Effective Tax Rate | 17.68% | 27.30% | 22.98% | 18.90% | 24.32% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.